Protective role of fentanyl in lipopolysaccharide-induced neuroinflammation in BV-2 cells
Authors:
- 1 October 2018
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (4) , 3740-3744
Abstract
Neurosurgery always results in neuroinflammation, which may activate microglial cells. Previous studies have demonstrated that fentanyl could be used for the induction or maintenance of anesthesia prior to surgery. However, it is unknown if fentanyl attenuates neuroinflammation prophylactically. Cell viability in groups that were treated with different concentrations of fentanyl (0.01, 0.1, 1 or 5 mu mol/l) was analyzed by an MTT assay. BV-2 microglial cells were treated with lipopolysaccharide (LPS) at a concentration of 1 mu g/ml to mimic neuroinflammation in vitro. BV-2 cells were pretreated with 5 mu mol/l fentanyl prior to stimulation by LPS. The protein levels of tumor necrosis factor (TNF)-, interleukin (IL)-1 and IL-10 in the culture medium were assessed by ELISA. The mRNA level of toll-like receptor (TLR)4 was evaluated by reverse transcription-quantitative polymerase chain reaction analysis. The protein levels of TLR4, glycogen synthase kinase (GSK)-3 and phosphorylated (p)-GSK-3 in BV-2 cells were assessed by western blot analysis. The MTT assay demonstrated that low concentrations of fentanyl (0.01, 0.1 or 1 mu mol/l) did not affect the cell viability of BV-2 cells, while 5 mu mol/l fentanyl significantly reduced BV-2 cell viability. The results of ELISA revealed that LPS significantly upregulated the release of TNF-, IL-1 and IL-10, which were repressed by fentanyl pretreatment. Fentanyl pretreatment significantly reduced the LPS-induced elevation of TLR4 at mRNA and protein levels as well as p-GSK-3 protein levels in BV-2 cells. In conclusion, fentanyl pretreatment protects BV-2 cells from LPS-induced neuroinflammation by inhibiting TLR4 expression and GSK-3 activation. Neuroinflammation induced by surgery serves an important role in the development of postoperative cognitive dysfunction (POCD) and targeting the TLR4 and GSK-3 signaling pathway may provide a novel therapeutic approach for the treatment of POCD.Keywords
This publication has 35 references indexed in Scilit:
- Toll‐like receptor‐4 knockout mice are more resistant to optic nerve crush damage than wild‐type miceClinical & Experimental Ophthalmology, 2015
- Neuroprotective Effects of Pretreatment with Propofol in LPS-Induced BV-2 Microglia Cells: Role of TLR4 and GSK-3βInflammation, 2012
- Bone marrow-derived mesenchymal stem cells modulate BV2 microglia responses to lipopolysaccharideInternational Immunopharmacology, 2010
- Walnut Extract Inhibits LPS-induced Activation of Bv-2 Microglia via Internalization of TLR4: Possible Involvement of Phospholipase D2Inflammation, 2010
- The potential for μ‐opioid receptor agonists to be anti‐emetic in humans: a review of clinical dataActa Anaesthesiologica Scandinavica, 2010
- Transdermal fentanyl: Pharmacology and toxicologyJournal of Medical Toxicology, 2009
- Systemic LPS causes chronic neuroinflammation and progressive neurodegenerationGlia, 2007
- The role of inflammation in CNS injury and diseaseBritish Journal of Pharmacology, 2006
- The Toll-Like Receptor TLR4 Is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNSThe Journal of Neuroscience, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001